

OTRU Competing Interest Policy

As a credible source of science-based information in the field of tobacco control, the Ontario Tobacco Research Unit (OTRU) is committed to transparency regarding sources of support and other relationships that might constitute, or give the appearance of, a conflict of interest. OTRU has implemented two policies in this regard:

1. OTRU does not accept grants, contracts, honoraria, contributions or anything else of value from any tobacco manufacturer, distributor, or other tobacco related company.

OTRU Principal Investigators, Directors, Scientists, Investigators, Affiliates and Student members are asked to declare that they do not currently accept nor will accept during their employment or membership with OTRU, any grants, contracts, salary, honoraria, contributions or anything else of fiduciary value from any tobacco manufacturer, distributor, or other tobacco related company.

Further, OTRU award recipients and their departmental Chair and academic supervisor (where applicable) are asked to declare that they or their department do not currently accept nor will accept during the grant period with OTRU, any grants, contracts, salary, honoraria, contributions or anything else of fiduciary value from any tobacco manufacturer, distributor, or other tobacco related company.

2. OTRU Principal Investigators and Directors are asked to disclose on an annual basis their past (within the last 12 months) or pending relationships with industries, institutions, agencies and organizations.

Disclosures of OTRU Directors and Principal Investigators

Robert Schwartz, Principal Investigator and Executive Director

Robert Schwartz, Executive Director and OTRU Principal Investigator, is an Associate Professor in the Dalla Lana School of Public Health at the University of Toronto. Dr. Schwartz has had no relationship with the tobacco industry. He has been a principal investigator on contracts between OTRU and Health Canada, the Alberta Cancer Board, the Heart and Stroke Foundation of Canada and Cancer Care Ontario. In 2007, he received a grant from the Canadian Tobacco Control Research Initiative (CTCRI). He has received travel and other support from Carleton University, the Kettering Institute, Health Canada, Canadian Council for Tobacco Control, Canadian Partnership Against Cancer, and the Roswell Park Cancer Institute. He is also a member of the Lung Association's Smoke-Free Homes and Asthma Advisory Committee and was a member of the Lungs Are for Life Advisory Committee (Ontario Lung Association and Ontario Physical and Health Education Association).

Roberta Ferrence, Principal Investigator and Deputy Director

Roberta Ferrence, Deputy Director and OTRU Principal Investigator, is a Senior Scientist with the Centre for Addiction and Mental Health, and Professor in the Dalla Lana School of Public Health at the University of Toronto. Dr. Ferrence has had no relationships with the tobacco industry or with the pharmaceutical industry in the past year. In 2010, she held grants as PI, co-Pi or co-investigator from the Ministry of Health Promotion and Sport, the Canadian Institute of Health Research (CIHR) and the Heart and Stroke Foundation. She has accepted travel support and reimbursement from Health Canada, the Society for Research in Nicotine and Tobacco, and the Canadian Partnership Against Cancer conference.

Joanna Cohen, Principal Investigator

Joanna Cohen, OTRU Principal Investigator, is the Bloomberg Associate Professor of Disease Prevention and the Director of the Institute of Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health, and an Associate Professor in the Dalla Lana School of Public Health at the University of Toronto. Dr. Cohen has had no relationships with the tobacco or pharmaceutical industries. In 2010-11, she received grant funding from the Canadian Institutes of Health Research, Health Canada, Bloomberg Philanthropies and the Flight Attendants Medical Research Institute. She received an honorarium from the journal Tobacco Control (as a senior editor).

Susan Bondy, Principal Investigator

Susan Bondy, OTRU Principal Investigator, is an Associate Professor in the Dalla Lana School of Public Health at the University of Toronto. Dr. Bondy has had no relationship with the tobacco industry. She has been an investigator for the Smoking Treatment for Ontario Patients (STOP) Study, in partnership with Johnson & Johnson, maker of nicotine replacement products. She has received research funds from the US National Institute of Alcohol Abuse and Alcoholism (NIAAA), the Canadian Institutes of Health Research (CIHR), the Canadian Tobacco Control Research Initiative (CTCRI) and the Canadian Cancer Society (CCS). She has performed contracted work for the Public Health Agency of Canada, the College of Physicians and Surgeons of Canada, the Canadian Public Health Association the Canadian Stroke Network and other public health-related agencies, none of which represent a conflict with her tobacco-control research or public health interests. She has also received grant review honoraria from the Workplace Safety and Insurance Board, the Alberta Cancer Board, and other non-profit agencies.

Stephen Brown, Principal Investigator

Stephen Brown, OTRU Principal Investigator, is a Professor in the Department of Statistics and Actuarial Science at the University of Waterloo, Co-Director of the Population Health Research Group and a Research Scientist with the Centre for Behavioural Research and Program Evaluation (CBRPE). Dr. Brown has had no relationship with the tobacco industry. He has a contract with Public Works, Government Services, Canada, for the Youth Smoking Survey, and has just completed one with Cancer Care Ontario. He has grants from Canadian Institutes of Health Research (CIHR), Canadian Tobacco Control Research Initiative (CTCRI), the National Institutes of Health (US), and the Ontario Ministry of Health Promotion. He is part of a group that receives funds from the Bill and Melinda Gates Foundation. In the past few years, he had a contract with a pharmaceutical company for statistical consulting services for a non-tobacco product; he accepted honoraria from the Michael Smith Foundation for a grant review; his expenses to participate in CIHR grant review panel were covered by CIHR; and he received funds to attend and speak at the Annual Invitational Symposium for Research in Tobacco Control. He is a National Cancer Institute of Canada (NCIC) consultant (unpaid) for CBRPE.

Paul McDonald, Principal Investigator

Paul McDonald, OTRU Principal Investigator, is a Professor and Director of the School of Public Health and Health Systems at the University of Waterloo. He is also member of the Board of Directors for the Waterloo-Wellington Local Health Integration Network. Dr. McDonald has had no relationship with the tobacco industry, and has not accepted financial support from the pharmaceutical industry for the past eight years. He has received research grants and contracts from several public agencies including the Canadian Institutes of Health Research, the Heart and Stroke Foundation, the Canadian Cancer Society,

provincial Ministries of Health and Health Canada. He has acted as a paid consultant/advisor to various public and non-profit health organizations.

John Garcia, Principal Investigator

John Garcia, OTRU Principal Investigator, is an Associate Professor and Associate Director, Professional Graduate Programs at the University of Waterloo School of Public Health and Health Systems. He is also an Associate Professor in the Department of Health Studies and Gerontology at the University of Waterloo and the Dalla Lana School of Public Health at the University of Toronto. Dr. Garcia has no contractual, grant, or other financial relationship with the tobacco or pharmaceutical industry. Being active in tobacco control and other aspects of public health practice, he engages in collaborative projects regularly with scientists, policy makers, and practitioners in public, private, and voluntary sector organizations.

Peter Selby, Principal Investigator

Peter Selby, OTRU Principal Investigator, is Clinical Director of the Addictions Program and Head of the Nicotine Dependence Clinic at the Centre for Addiction and Mental Health, and an Associate Professor in the Departments of Family and Community Medicine, Psychiatry and the Dalla Lana School of Public Health at the University of Toronto. Dr. Selby has no relationship with the tobacco industry.

He has received funds from Schering Canada to provide buprenorphine training (2000). He has acted as a paid consultant for Astro-Zeneca Canada Inc.; Johnson and Johnson Consumer Health Care Canada; Pfizer Inc. Canada; Pfizer Global; Sanofi-Synthelabo, Canada; GlaxoSmithKline, Canada; Genpharm and Prepharm Canada; NABI Pharmaceuticals; V-CC Systems Inc. & EHealth Behaviour Change Software Co.; and Schering Canada.

He has also received honoraria or been part of a speakers bureau for Schering Canada; Johnson and Johnson Consumer Health Care, Canada; Pfizer Inc. Canada; Pfizer Global; Sanofi-Synthelabo Canada; Glaxo Smith Kline Canada; Genpharm & Premfarm Canada and NABI Pharmaceuticals.

His grant funding has come from Health Canada, Smoke-Free Ontario, Ministry of Health Promotion and Sport, Canadian Tobacco Control Research Initiative (CTCRI), Alberta Health Services (formerly Alberta Cancer Board), Vancouver Coastal Authority, Canadian Institutes of Health Research (CIHR), Pfizer, Ontario Lung Association (OLA), ECHO, National Institute on Drug Abuse (NIDA), and Canadian Cancer Society (CCS).